David E. Galey, Ph.D. - Publications
Affiliations: | 2005 | University of Kentucky, Lexington, KY |
Area:
ImmunologyYear | Citation | Score | |||
---|---|---|---|---|---|
2007 | Steiner JP, Galey D, Haughey NJ, Asch D, Nath A. Neuroprotective and antiretroviral effects of the immunophilin ligand GPI 1046. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 2: 49-57. PMID 18040826 DOI: 10.1007/S11481-006-9060-0 | 0.51 | |||
2006 | Caporello E, Nath A, Slevin J, Galey D, Hamilton G, Williams L, Steiner JP, Haughey NJ. The immunophilin ligand GPI1046 protects neurons from the lethal effects of the HIV-1 proteins gp120 and Tat by modulating endoplasmic reticulum calcium load. Journal of Neurochemistry. 98: 146-55. PMID 16805804 DOI: 10.1111/J.1471-4159.2006.03863.X | 0.506 | |||
2006 | Patel J, Galey D, Jones J, Ray P, Woodward JG, Nath A, Mumper RJ. HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and neutralizing antibodies compared to alum adjuvant. Vaccine. 24: 3564-73. PMID 16516358 DOI: 10.1016/J.Vaccine.2006.01.065 | 0.418 | |||
2005 | Hollman AM, Christian DA, Ray PD, Galey D, Turchan J, Nath A, Bhattacharyya D. Selective isolation and purification of tat protein via affinity membrane separation. Biotechnology Progress. 21: 451-9. PMID 15801785 DOI: 10.1021/Bp049804Z | 0.419 | |||
2004 | Conant K, St Hillaire C, Anderson C, Galey D, Wang J, Nath A. Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases. Journal of Neurovirology. 10: 21-8. PMID 14982725 DOI: 10.1080/13550280490261699 | 0.422 | |||
Show low-probability matches. |